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(Aβ)  peptides and intraneuronal neurofi brillary tangles (NFTs) 
 composed of aggregated phosphorylated tau. Aβ peptides, the 
principal constituents of amyloid plaques, stimulate glial cells 
to undergo morphological and gene expression changes causing 
activation and/or secretion of proinfl ammatory molecules includ-
ing cytokines, complement components, adhesion molecules and 
cyclooxygenase (COX) enzymes (Mrak and Griffi n, 2005). Once 
activated, microglia and astrocytes contribute to removal of Aβ 
from the brain parenchyma (Wyss-Coray et al., 2001, 2003). By 
contrast, long-term chronic infl ammatory responses contribute 
actively to neuron dysfunction and further neurodegeneration 
in AD, which suggests that infl ammation may have early benefi ts 
as well as long-term detrimental effects during progression of 
the disease.
The prevalent hypothesis of AD postulates that one of the 
initiating events of the disease is related to abnormal process-
ing, aggregation and/or clearance of Aβ peptides (Hardy and 
Selkoe, 2002). The initial accumulation of Aβ peptides and/or 
phosphorylated tau may occur when individuals are still cogni-
tively normal, whereas accumulation of Aβ in plaques and the 
presence of NFTs accompanied by neuronal dysfunction and 
neurodegeneration correlate closely with severity of clinical 
symptoms (Jack et al., 2010). At initial stages, accumulation of 
aggregated oligomeric Aβ species can interfere with neuronal and 
INTRODUCTION
Infl ammation is the main biological defense mechanism in 
response to external injury. Besides having multiple therapeutical 
benefi ts, infl ammation has been extensively implicated in many 
pathological conditions including cancer, diabetes, heart infarct 
and brain diseases. Infl ammatory responses are common in acute 
and chronic diseases of the central nervous system. For instance, 
inappropriate infl ammation contributes directly to acute neurode-
generation during brain stroke, trauma and viral infection (Allan 
and Rothwell, 2003). Similarly, chronic infl ammatory responses 
are also common to many age-related neurodegenerative disorders 
including Alzheimer’s disease (AD). Neuroinfl ammatory responses, 
characterized by activation of glial cells, especially microglia and 
astrocytes, and increased production of infl ammatory molecules 
are closely associated to neuropathological lesions in AD brain 
(Mrak and Griffi n, 2005). Moreover, infl ammation is an important 
neuropathological feature that contributes to neuronal dysfunction 
and cognitive dysfunction during normal aging and age-related 
neurodegenerative conditions (Lynch, 2010).
AD is the most common neurodegenerative disorder in the 
elderly. AD causes progressive cognitive impairment and behav-
ioral disturbances leading fi nally to dementia. The classical neu-
ropathological features of AD brain include neuronal loss and the 
presence of extracellular amyloid plaques containing β-amyloid 
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 synaptic function without affecting neuronal viability. The key step 
 regulating Aβ generation is the sequential proteolytic processing 
of amyloid precursor protein (APP) by β-secretase (BACE) and 
γ-secretase proteases. Presenilins (PS), the catalytic components 
of γ-secretase, are essential for Aβ generation, age-dependent Aβ 
accumulation and infl ammatory responses during progression of 
the disease (Saura et al., 2005). Therefore, modulation of γ-secre-
tase by using specifi c inhibitors has been suggested as potential 
therapeutic strategy to reduce Aβ-induced pathology and clinical 
symptoms. Interestingly, some non-steroidal anti-infl ammatory 
drugs (NSAIDs) that ameliorate symptoms and reduce the risk of 
AD were shown to lower the generation of Aβ42 by affecting the 
γ-secretase-dependent cleavage of APP (Weggen et al., 2007). The 
therapeutic benefi ts of PS/γ-secretase inactivation may directly 
depend on the target selectivity and reduction of side effects on 
other important signaling pathways.
Here, I describe recent fi ndings implicating PS/γ-secretase on 
infl ammation, especially those related with cellular and genetic 
mechanisms regulated by PS during infl ammatory responses in 
brain diseases. Finally, I discuss implications for development and 
ongoing therapeutic strategies based on γ-secretase targeting and 
modulation in AD.
PRESENILIN BIOLOGY
PS are multifunctional proteins that contain the catalytic core 
of γ-secretase, an aspartyl protease that mediates the regulated 
intramembrane cleavage of multiple cell surface signaling pro-
teins including among others APP, Notch receptors, ErbB4, E- 
and N-cadherins, p75 and EphB2 (Koo and Kopan, 2004). PS are 
transmembrane proteins that undergo regulated endoproteolysis 
to generate N- and C-terminal fragments, which are the predom-
inant PS species that accumulate in vivo within the enzymatic 
complex (Thinakaran et al., 1996; Saura et al., 1999). The func-
tional active γ-secretase complex is composed of PS dimers and 
other components such as nicastrin, Pen-2 and Aph1 (De Strooper, 
2003; Cervantes et al., 2004). These four components are essential 
for stabilization and function of γ-secretase. The mechanism of 
complex assembly involves stabilization of full-length presenilin 
by Aph-1/nicastrin, followed by binding of Pen-2, which facilitates 
endoproteolysis of presenilin and confers the γ-secretase activity 
(Takasugi et al., 2003).
Two presenilin homologous presenilin-1 (PS1) and presenilin-2 
(PS2) located on chromosomes 14q24.3 and 1q31-q42, respectively, 
are present in mammals. Gene expression studies in different spe-
cies have revealed wide-spread expression of PS in different cell 
types and tissues. PS1 and PS2 are ubiquitously expressed in most 
tissues including the brain (Lee et al., 1996; Lah et al., 1997). During 
mouse development, PS1 mRNA expression is particularly high in 
neural organs, whereas PS2 is barely expressed. By contrast, PS1 and 
PS2 mRNAs are highly expressed in neurons of the hippocampus 
and entorhinal cortex in adult mouse brain (Lee et al., 1996). In 
human brain, PS1 protein is highly expressed in pyramidal neurons 
of the hippocampus and neocortex, magnocellular neurons of the 
basal forebrain, brainstem motoneurons and some interneuron 
populations (Kim et al., 1997; Lah et al., 1997). Although PS are 
mainly expressed in neurons, PS1 and PS2 mRNAs are detected at 
low levels in white matter glial cells and cultured astrocytes (Lee 
et al., 1996). However, PS1 expression is upregulated in reactive 
astrocytes and activated microglia under pathological conditions 
such as those occurring in AD, brain injury and hypoxia (Weggen 
et al., 1998; Peers et al., 2004; Nadler et al., 2008).
ROLE OF PRESENILINS ON GLIOGENESIS
γ-Secretase facilitates Notch signaling by mediating the ligand-
induced proteolytic cleavage of Notch1 receptor that generates 
the Notch intracellular domain (NICD) (De Strooper et al., 1999). 
NICD then translocates to the nucleus where binds to CBF1/RBPJk/
Su(H)/Lag1 (CSL) family of transcriptional activators or repressors 
that participate in the transcriptional control of downstream target 
genes. The function of the Notch signaling pathway is specially rel-
evant for controlling cell fate decisions during development. Notch 
signaling mediates neural stem cell survival, self-renewal, prolifera-
tion and cell fate specifi cation during central nervous system devel-
opment (Lathia et al., 2008). In this way, Notch signaling maintains 
neural progenitor cells in a proliferative stage, inhibits neuronal 
differentiation and specifi es radial glial cell fate (Gaiano and Fishell, 
2002). Activation of Notch-1 and Notch-3 in embryonic progenitors 
promotes radial glial fate and astrocyte fate postnatally (Gaiano 
et al., 2000). Accordingly, PS1-defi cient mice show disturbed neu-
rogenesis and somite formation, premature differentiation of pro-
genitor cells accompanied by severe brain morphological defects 
resembling Notch mutants (Handler et al., 2000). Therefore, PS/γ-
secretase-dependent Notch signaling promotes glial and astrocytic 
fates in the developing and adult brain (Figure 1).
By contrast, PS/γ-secretase represses the astrocytic fate of embry-
onic neural precursors in the developing brain by regulating the 
activation of the tyrosine kinase receptor ErbB4. Similarly to Notch 
processing, upon neuregulin binding and activation of ErbB4, 
γ-secretase releases the intracellular domain of ErbB4 (Ni et al., 
2001), which then binds to TAB2 and the corepressor N-CoR (Sardi 
et al., 2006). This complex translocates to the nucleus and represses 
expression of astrocytic genes required for astrocyte fate, an obser-
vation that agrees with accelerated astrogenesis observed in ErbB4 
knockout mice (Sardi et al., 2006). Thus, PS/γ-secretase-dependent 
nuclear signaling and gene transcription by ErbB4 directly regulates 
glial fate specifi cation (Figure 1).
PRESENILIN/γ -SECRETASE IN ALZHEIMER’S DISEASE AND 
FRONTOTEMPORAL DEMENTIA
γ-Secretase plays a critical role on AD pathogenesis by mediating the 
generation of Aβ peptides. Aβ generation results from the extracel-
lular cleavage of APP by BACE1 and after shedding of the soluble 
ectodomain (APPsβ), PS/γ-secretase cleaves the transmembrane 
domain of the APP C-terminal fragment to generate Aβ peptides 
of variable length (39–43 aa) (Selkoe, 2002). PS/γ-secretase also 
cleaves APP on the ε-cleavage site to generate the APP intracel-
lular domain (AICD), a cytosolic fragment that translocates to the 
nucleus, activates gene expression and regulates apoptotic cell death 
(Muller et al., 2008). Presenilin is essential for generation and accu-
mulation of Aβ, as evidenced by the lack of Aβ production in cells 
derived from PS1 and PS1/PS2 defi cient mice (De Strooper et al., 
1998; Zhang et al., 2000) and the absence of Aβ accumulation and 
amyloid plaques in the brain of APP transgenic mice lacking PS1 
expression (Saura et al., 2005) (Figure 2).
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The fi rst evidence linking PS and AD came from the  discovery 
that autosomal dominant mutations in the PSEN1 gene were 
responsible for early-onset familial AD (Sherrington et al., 1995). 
This was followed by the fi nding that inherited mutations in PSEN2 
caused AD with variable penetrance and later onset (Levy-Lahad 
et al., 1995; Rogaev et al., 1995). A large number of mutations in 
PSEN1 (∼170) and PSEN2 (14) are currently known to cause the 
majority (∼30–50%) of familial AD cases1 (http://www.molgen.
ua.ac.be/ADMutations). Mutations in PS alter the cleavage of APP 
resulting in generation of distinct amyloidogenic Aβ peptides. Thus, 
several mutations in distinct domains of PS1 (EΔ9, A79V, I143T, 
L166P, A231V, L262F, L282V, G384A) or PS2 (N141I) decrease 
total Aβ or Aβ40 levels with little or unappreciable changes on 
the more amyloidogenic Aβ42 species (Kumar-Singh et al., 2006; 
De Strooper, 2007). Other studies have demonstrated increased 
Aβ42(43) peptides, and/or increased Aβ42/Aβ40 ratio in cells 
or transgenic mice expressing mutant PS1 or PS2 genes (Selkoe, 
2002). The concentration balance of different Aβ species seems to 
be important for aggregation and their toxic effects in AD brain. 
Notably, the age of onset of dementia in families with PS mutations 
correlates with increase of Aβ42/Aβ ratio and decrease Aβ40 levels 
(Kumar-Singh et al., 2006). The fact that PS pathogenic mutations 
suppress the γ- and/or ε-secretase cleavage of several substrates 
including APP has lead to the hypothesis that these mutations may 
act through a loss of function mechanism (De Strooper, 2007; Shen 
and Kelleher III, 2007).
FIGURE 1 | Mechanisms regulating brain infl ammation by PS/
γ-secretase. Schematic model showing signaling mechanisms regulated by 
PS/γ-secretase on infl ammation. The γ-secretase-dependent cleavage of APP 
generates the Aβ peptide that following oligomerization (Aβ olig) accumulates 
in plaques in AD brain (dashed lines). Aβ stimulates infl ammatory cells that 
upon activation upregulate proinfl ammatory genes and secrete infl ammatory 
molecules. Activated microglia and reactive astrocytes accumulate 
surrounding the amyloid plaques. Non-steroidal anti-infl ammatory drugs 
(NSAIDs) reduce infl ammation by acting through different molecular 
mechanisms including inhibition of COX enzymes in microglia or by reducing 
Aβ42 generation through γ-secretase or BACE1. On the other hand, the γ-
secretase-dependent cleavage of Notch receptor generates the Notch 
intracellular domain (NICD), which promotes radial glial and astrocyte fates in 
neural precursor cells (NPC) by affecting target gene expression. By contrast, 
γ-secretase-dependent cleavage of ErbB4 generates the ErbB4 intracellular 
domain (EICD) that represses expression of astrocytic genes. In addition, PS 
downregulate the expression of infl ammatory genes in glial cells by still 
unknown mechanisms.
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Mutations in the presenilin genes accelerate age of onset and 
cause earlier and severe progression of neurodegeneration than 
sporadic AD. The presence of some PS mutations results in quan-
titative differences in brain neuropathology compared to sporadic 
forms of AD (Shepherd et al., 2009). Thus, despite similar disease 
duration, familial cases show similar or greater atrophy and neu-
ronal loss, specially in the medial temporal lobes and frontal/tem-
poral cortices, than sporadic AD cases (Gomez-Isla et al., 1999; 
Gregory et al., 2006; Shepherd et al., 2007). Similarly, an increase 
of NFTs and higher NFT-associated neuritic pathology have been 
reported in PS-linked familial AD cases compared to sporadic AD 
(Gomez-Isla et al., 1999; Sudo et al. 2005; Woodhouse et al. 2009). 
Several studies have also shown increased overall amyloid plaques, 
especially those containing higher deposition of Aβ42 in genetics 
forms of AD (Shepherd et al., 2009). By contrast, other reports show 
similar amyloid plaque deposition in PSEN1 and sporadic AD cases 
(Nochlin et al., 1993; Lippa et al., 1996). The distinct effect of PS 
mutations on disease progression may refl ect a differential effect 
of PS mutations on Aβ processing, tau phosphorylation and other 
signaling pathways (GSK3β, β-catenin, calsenilin, Notch, CREB, 
E/N-cadherin, etc…).
Genetic studies have identifi ed PSEN1 mutations in families 
presenting clinical symptoms of frontotemporal dementia (FTD), 
atypical dementia with a FTD phenotype and dementia with Lewy 
bodies (Hutton, 2004). For instance, the PSEN1 L424H mutation 
causes FTD characterized by AD neuropathology, whereas the 
PSEN1 V272A mutation is associated with subcortical dementia 
with Lewy body pathology (Zekanowski et al., 2006; Gomez-Tortosa 
et al., 2010). Several mutations in PSEN1 including L113P, G183V, 
L226F and V412I have been found in early-onset familial FTD (Raux 
et al., 2000; Dermaut et al., 2004; Bernardi et al., 2009). These PSEN1 
mutations cause severe neurodegeneration and dementia associ-
ated with accumulation of phosphorylated tau in the absence of 
Aβ pathology in the frontal cortex. Thus, the G183V mutation 
increases the levels of phosphorylated tau without affecting Aβ2 
levels and deposition (Dermaut et al., 2004). Consistent with a role 
FIGURE 2 | PS1 inactivation reduces brain infl ammation in APP 
transgenic mice. The images show consecutive serial brain sections of 
6 month-old APP (APPSw,Ind; J20) and PS1cKO;APP transgenic (Tg) mice 
stained with antibodies against Aβ42, GFAP and CD45. Reactive astrocytes 
labeled with a GFAP antibody and activated microglia stained with 
anti-CD45 are found in the hippocampus of APP mice, but not in 
PS1cKO;APP mice. Activated microglia and astrocytes in APP brains are 
closely associated with Aβ42-containing plaques as observed in these three 
consecutive brain sections. Insets: Higher-power views of the lesions marked 
with arrowheads.
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of PS on tau phosphorylation, overexpression of mutant PS1 in mice 
results in activation of GSK-3β and enhanced phosphorylation of 
tau (Dewachter et al., 2008). Interestingly, inactivation of both PS1 
and PS2 in the adult mouse brain leads to increased phosphorylation 
of tau and age-dependent memory defi cits and neurodegeneration 
(Saura et al., 2004). This raises the possibility that some PS patho-
genic mutations may cause memory defi cits and neurodegeneration 
by affecting tau phosphorylation and/or aggregation.
PRESENILINS AND BRAIN INFLAMMATION
Abundant infl ammation correlates with the initial cognitive 
decline and severity of dementia in AD (Parachikova et al., 2007). 
Reactive glial cells, especially activated microglia and astrocytes, 
and increased production of infl ammatory molecules are associated 
to neuritic plaques (Holmes et al., 2009). Activation of microglia 
is initiated by local binding of fi brillar Aβ to C1q receptors and a 
receptor complex formed by the β-class scavenger receptor CD36, 
the integrin-associated protein/CD47, and the α(6)β(1)-integrin 
(Eikelenboom and Veerhuis, 1996; Bamberger et al., 2003). The 
subsequent activation of intracellular signaling pathways in micro-
glia leads to the proinfl ammatory response. Microglia activation 
induces secretion of cytokines and other neuroinfl ammatory mol-
ecules that promote stimulation and activation of astrocytes around 
the plaques. Once activated, microglia and astrocytes contribute 
actively to removal of Aβ from the brain parenchyma (Wyss-Coray 
et al., 2001, 2003), as revealed by accumulation of Aβ42 peptides 
in astrocytes in AD brain (Nagele et al., 2003).
An increase of neuroinfl ammatory mediators resulting from 
enhanced amyloid pathology in familial AD or as a direct conse-
quence of PS mutations may have detrimental consequences for 
neuronal function. Monocyte chemoattractant protein-1 (MCP-
1), interleukin-6 (IL-6) and interleukin-8 (IL-8) are increased 
by familial AD-linked PS mutations (Sokolova et al., 2009), and 
mutant PS1 enhances expression of microglial factors that promote 
differentiation of neural precursor cells into glial fi brillary acidic 
protein (GFAP)-positive cells (Choi et al., 2008). Production of 
infl ammatory cytokines like IL-1β, IL-6 and TNFα by activated 
microglia, but also by reactive astrocytes, negatively impact on neu-
ronal function and behavior. For instance, secretion of toxic neu-
roinfl ammatory mediators such as reactive oxygen species (ROS), 
cytokines and chemokines directly contributes to neurite retraction, 
neuronal dysfunction and neuronal death in AD (Munch et al., 
2003; Sokolova et al., 2009). Nonetheless, infl ammatory cytokines 
have been suggested to be the primary contributors to synaptic 
plasticity defi cits and behavioral changes during normal aging and 
age-dependent neurological diseases (Lynch, 2010). Recent fi ndings 
demonstrate that overexpression of IL-1β in the hippocampus is 
accompanied by microglial activation and increased expression of 
chemokines MCP-1 and MIP-1, which negatively affect hippocam-
pal- dependent memory (Moore et al., 2009). The negative impact 
of chronic infl ammation on synaptic function during neurodegen-
eration has been corroborated in several studies in aged and AD 
transgenic mice (McGeer and McGeer, 2007).
Besides the classic neuritic plaques, cotton wool and ‘infl am-
matory’ plaques are specifi c pathological hallmarks commonly 
observed in familial AD caused by PS mutations. Cotton wool 
plaques, which are composed mainly of Aβ42, are usually devoid of 
a compact amyloid core, neuritic changes and glial cell  components 
(Mann et al., 2001). Cotton wool plaques are mainly detected in 
neocortex, limbic system and striatum in AD cases caused by PSEN1 
mutations in exons 4, 5, 6, 8, 9 and 12 and intron 8 (Mann et al., 
2001; Dumanchin et al., 2006), whereas they are very rare in late-
onset AD (Le et al., 2001). By contrast, ‘infl ammatory plaques’ are 
small dense plaques with a central core devoid of Aβ, phosphor-
ylated tau, ApoE and α-synuclein. ‘Infl ammatory plaques’ display 
a strong infl ammatory response in the form of numerous activated 
microglia and astrocytes in the cortex of familial AD cases linked to 
PSEN1 and APP mutations (Shepherd et al., 2005). The increase of 
infl ammatory cells surrounding these plaques may contribute sig-
nifi cantly to greater neuronal dysfunction and neurodegeneration 
in some genetic AD cases linked to PS mutations (Shepherd et al., 
2009). The variability on clinical symptoms and brain pathology 
in subjects carrying the same PS1 mutation (Martikainen et al., 
2009), suggests that other genetic, cellular or environmental factors 
may alter the pathological phenotypes in genetically predetermined 
familial AD cases.
PRESENILINS AND BRAIN INJURY
Epidemiological studies indicate that head trauma is an important 
risk factor for developing AD. Levels of PS1 and nicastrin increase 
signifi cantly in activated astrocytes and microglia following brain 
damage by head injury, brain stabbing and infl ammatory insult 
(Nadler et al., 2008). Indeed, chronic cortical gliosis and infl am-
matory mediators stimulate APP metabolism and elevate Aβ 
peptides by increasing expression of APP and PS1, which in turn 
affects glial activation and neuronal function (Bates et al., 2002). 
Increased expression of mutant PS1 in astrocytes has been shown 
to contribute to astrocyte reactivity in response to ATP and gluta-
mate through a mechanism involving increased Ca2+ oscillations 
(Johnston et al., 2006). This result indicates that PS1 mutations 
enhance intracellular Ca2+ mobilization in astrocytes contributing 
to the accelerated pathogenesis in familial AD. Similarly, PS1 expres-
sion increases in astrocytes under hypoxia conditions contributing 
to enhancement of intracellular calcium, whereas inhibition of PS1 
reverses the effects of hypoxia on calcium signaling (Peers et al., 
2004). Interestingly, hypoxia increases Aβ levels by affecting APP 
processing and/or Aβ clearance. The role of PS on brain hypoxia 
and its association to dementia is particularly intriguing since 
hypoxia, which can arise from cardiorespiratory diseases, predis-
pose individuals to the development of dementias and especially 
to AD (Peers et al., 2009).
Brain ischemia is known to contribute to AD dementia, whereas 
individuals with severe cognitive decline and diagnosis of AD are 
at increased risk for ischemic events in the brain. PS/γ-secretase 
seems to mediate the effect of Notch on ischemia events. In a mouse 
model of ischemic stroke, Notch increases the vulnerability of cells 
to undergo apoptosis, activates microglial cells and stimulates infi l-
tration of proinfl ammatory leukocytes (Arumugam et al., 2006). By 
contrast, γ-secretase inhibitors and expression of a Notch1 antisense 
reduce brain damage and improve neural function in that experi-
mental model of ischemic stroke (Arumugam et al., 2006). Given 
that PS/γ-secretase-mediated Notch signaling worsens brain dam-
age during ischemic stroke, it has been suggested that agents that 
target Notch function may be useful for therapeutic  interventions 
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in some brain disorders (Lathia et al., 2008). These fi ndings indicate 
that PS may contribute to brain damage and/or repair by regulating 
glial activation and function.
PRESENILINS IN THE PERIPHERAL IMMUNE SYSTEM
Enhanced cell death and calcium signaling defects in peripheral 
lymphocytes have been demonstrated in AD patients, suggesting 
that immune dysfunction can contribute to the pathogenesis of AD. 
Defects on T-cell activation by a PS1 mutation that causes familial 
AD has been reported in mutant PS knockin mice (Morgan et al., 
2007). Lymphocytes from PS1 mutant transgenic mice show higher 
susceptibility to cell death as do peripheral cells from AD patients, 
which is likely caused by increased production of ROS and altered 
calcium levels (Eckert et al., 2001). Notably, lack of presenilins 
in the brain leads to robust infl ammatory responses both in the 
brain and periphery. Beginning at 6 months of age, and coinciding 
with the neurodegenerative process, leukocytes and infl ammatory 
mediators are elevated in serum of mutant PS1/PS2 conditional 
double knockout (PS cDKO) mice (Jiang et al., 2009). This fi nding 
indicates that infl ammatory responses in the brain rapidly expand 
to systemic tissue under pathological conditions caused by loss of 
PS function in the brain.
Notch signaling plays a critical role on lymphocyte develop-
ment by specifying T cell fate and differentiation. Notch signaling 
regulates CD4/CD8 T cell lineage commitment, whereas PS/γ-
secretase-dependent Notch signaling promotes the selection and 
maturation of CD4 and CD8 T cells in immature thymocytes (Laky 
and Fowlkes, 2008). A role of PS/γ-secretase on T cell fate is evi-
dent in PS-defi cient mice, in which lack of presenilin expression 
in thymocyte precursors ineffi ciently generate CD4+ T cells by 
impairing TCR signaling (Laky and Fowlkes, 2007). This has lead 
to the hypothesis that PS-dependent Notch signaling positively 
infl uences the selection and development of T cells by modifying 
TCR signaling. Similarly, inactivation of both PS in thymic cells 
results in a signifi cant decrease of CD8+ T cells in the periph-
ery (Maraver et al., 2007). However, whereas PS facilitate CD4+ 
T cell proliferation and cytokine secretion, they are not required 
for cytokine-induced Th1/Th2 fate selection (Ong et al., 2008). A 
direct role for PS proteins on B cell function has been also reported. 
Loss of PS function in B cells results in substantial defi cit in both 
lipopolysaccharide and B cell antigen receptor-induced prolifera-
tion and signaling events, including a defect in anti-IgM-mediated 
calcium fl ux (Yagi et al., 2008).
A mechanism that could mediate presenilin-dependent reg-
ulation of lymphocyte activation is CD46, a signaling receptor 
with complement and T cell regulatory functions in human. In 
response to infectious pathogens such as Neisseria gonorrhoeae 
and Neisseria meningitidis, processing of CD46 by PS/γ-secretase 
stimulates CD46-dependent T cell responses (Weyand et al., 2010). 
Therefore, PS/γ-secretase seems to be particularly important in 
response to pathogens by mediating the cleavage of CD46 and reg-
ulating signaling pathways in immune cells. Interestingly, PS1+/−; 
PS2−/− mice develop an autoimmune disease characterized by 
dermatitis, glomerulonephritis, keratitis and vasculitis. At advanc-
ing ages, these mutant mice develop skin hyperplasia, increased 
CD4+/CD8+ T cell ratio and B-cell infi ltrates in several tissues 
(Tournoy et al., 2004). Together, compelling evidence  suggests 
that PS/γ-secretase regulates maturation of T cells, whereas its 
 inactivation in the periphery has functional detrimental conse-
quences for immune system.
REGULATION OF INFLAMMATORY MECHANISMS BY PS
A number of recent studies using PS loss-of-function mutant mice 
has added a new view on the role of PS on neuroinfl ammation. 
Consistent with the idea that PS1/γ-secretase plays an essential 
role on AD pathogenesis, PS1 inactivation reduces signifi cantly 
age-dependent Aβ accumulation and amyloid plaque deposition 
in APP transgenic mice (Dewachter et al., 2002; Saura et al., 2005). 
Interestingly, conditional deletion of PS1 in the adult forebrain 
of APP transgenic mice reduces dramatically amyloid-associated 
microgliosis and astrocytosis (Figure 2), which is accompanied by 
reversal of hippocampal-dependent spatial and associative mem-
ory defi cits (Saura et al., 2005). Whereas these results suggest that 
PS1/γ-secretase is required for Aβ-induced neuroinfl ammatory 
responses, they also indicate that targeting PS1/γ-secretase may 
have therapeutic benefi ts in AD.
In contrast to the protective role of partial PS/γ-secretase 
inactivation on amyloid pathology and infl ammation, genetic 
ablation of both PS causes progressive infl ammatory responses 
in the cerebral cortex of PS cDKO mice. The early widespread 
infl ammatory response observed in PS cDKO mice is independ-
ent of Aβ accumulation and appears before synapse loss and tau 
hyperphosphorylation (Beglopoulos et al., 2004). Infl ammatory 
changes are the fi rst pathological hallmarks observed in PS cDKO 
mice and these are followed by synaptic and memory impair-
ments and progressive neurodegeneration (Saura et al., 2004). By 
3 months of age, and long before activated infl ammatory cells and 
neurodegeneration are apparent, several proinfl ammatory genes 
including complement component C1qα-β, cathepsins D and S, 
small inducible cytokine A27, MHC histocompatibility proteins 
and CD antigens are up-regulated in the cortex and hippocampus 
of PS cDKO mice (Dong et al., 2007). Abundant reactive infl am-
matory cells, including activated microglia and reactive astrocytes, 
are observed in the hippocampus and neocortex of PS cDKO 
mutant mice by 6 months of age (Beglopoulos et al., 2004; Saura 
et al., 2004). Gene expression profi le analyses in PS cDKO mice at 
that age have revealed an upregulation of multiple infl ammatory 
genes including complement component C1qα-β, MHC histo-
compatibility proteins, cathepsins D, H, S and Z, chemokines, CD 
antigens and GFAP (Beglopoulos et al., 2004; Dong et al., 2007). 
Interestingly, the complement system, which targets toxic sub-
stances in the immune system, is directly involved in the infl am-
matory responses in AD and Down syndrome patients (Tenner, 
2001). Cathepsin S, a lysosomal cysteine protease that is secreted 
by activated microglia and macrophages and mediates major histo-
compatibility class II-dependent immunity, is increased in AD and 
Down syndrome brains (Lemere et al., 1995). On the other hand, 
increased expression of GFAP, a marker of astrogliosis, correlates 
with progression of dementia and synaptic and tau pathologies 
in AD brain (Ingelsson et al., 2004).
Interestingly, cognitive stimulation by long-term environmental 
enrichment improved memory and reduced brain degeneration 
and astrogliosis in PS cDKO mice. Environmental enrichment sig-
nifi cantly reduced 34 genes related to immunity and  infl ammation 
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that were upregulated in the hippocampus of PS cDKO mice (Dong 
et al., 2007). These fi ndings suggest that the therapeutic benefi ts 
of cognitive stimulation may be in part related to inhibition of 
expression of infl ammatory genes. Together, the above evidence 
points to a role of PS on regulating directly or indirectly the expres-
sion of proinfl ammatory genes. Although the specifi c mechanisms 
by which PS repress expression of infl ammatory genes are still 
unknown, it is tempting to speculate that PS/γ-secretase-depend-
ent mechanisms, such as that involving repression of astrocytic 
genes by the ErbB4 intracellular domain (Sardi et al., 2006), might 
be involved on transcriptional regulation of infl ammatory genes 
during neurodegeneration (Figure 1).
PS/γ -SECRETASE AS PHARMACOLOGICAL 
TARGET OF NSAIDs
Epidemiological studies indicate that chronic treatment with NSAIDs 
delays the onset and reduces the risk of AD (Stewart et al., 1997; 
McGeer and McGeer, 2007). Prospective population-based cohort 
studies revealed that NSAID use for more than 2 years decreases 
by 60–80% the risk of developing AD but not vascular dementia 
(Stewart et al., 1997; in t’ Veld et al., 2001). Regular use of specifi c 
NSAIDs for 1 year or more than 5 years decreases the risk of AD 
signifi cantly from 2% to 34%, respectively (Vlad et al., 2008). For 
instance, ibuprofen and indomethacin, two NSAIDs that decrease 
Aβ42, showed a strong protective effect that increased with dura-
tion of use. By contrast, celecoxib and salicylates, two NSAIDs that 
do not affect Aβ42, did not show any protective effects (Vlad et al., 
2008). Randomized clinical studies with indomethacin for 6 months 
improved cognitive function in mild/moderate AD patients, whereas 
naproxen, rofecoxib, diclofenac or nimesulide revealed no cognitive 
benefi ts (McGeer and McGeer, 2007). R-fl urbiprofen, an enantiomer 
of fl urbiprofen that selectively lower Aβ42 and lacks COX inhibitory 
activity, did not slow cognitive decline or improved activities of daily 
living in phase III trials (Green et al., 2009). These differential effects 
of NSAIDs on AD may be caused by distinct activity of NSAIDs on 
COX-dependent or -independent mechanisms.
The molecular mechanisms by which NSAIDs reduce infl am-
mation and ameliorate clinical symptoms in AD are largely unclear. 
The classical mechanism of anti-infl ammatory action of NSAIDs 
involves reduction of prostaglandin synthesis through inhibition of 
COX enzymes (COX-1 and COX-2). NSAIDs have been also shown 
to activate the nuclear receptor peroxisome proliferator-activated 
receptor-γ (PPARγ) and inhibit expression of proinfl ammatory genes. 
Alternatively, NSAIDs inhibit Aβ42 generation by repressing BACE1 
expression through PPARγ and by regulating the presenilin/γ-secre-
tase-dependent cleavage of APP (Weggen et al., 2007). In support of 
a role of some NSAIDs on protecting from Aβ pathology through 
PPARγ, it has been shown that NSAIDs repress BACE expression 
and negatively modulate Aβ generation (Sastre et al., 2006), whereas 
acute treatments with ibuprofen or the PPARγ agonist pioglitazone 
reduce BACE1 expression and glial infl ammation in APP transgenic 
mice (Heneka et al., 2005). On the other hand, some NSAIDs affect 
Aβ levels by modulating γ-secretase activity, the non amyloidogenic 
α-secretase pathway and/or Aβ aggregation (Weggen et al., 2007). 
For instance, NSAIDs bind to and inhibit formation of Aβ fi brils 
in vitro (Agdeppa et al., 2003; Hirohata et al., 2005), a mechanism 
that may explain the  benefi cial effects of chronic treatment of ibu-
profen or R- fl urbiprofen on reducing amyloid deposits in very old 
APP transgenic mice (Lim et al., 2000; Kukar et al., 2007). A subset 
of NSAIDs induce a shift on the γ-secretase proteolytic cleavage of 
APP causing a specifi c decrease on the production of Aβ42 while 
increasing shorter Aβ species (i.e. Aβ38) and without affecting Aβ40 
(Weggen et al., 2001). Indeed, the generation of Aβ42 and Aβ38 
by γ-secretase is independent from each other and NSAID differ-
entially affect the levels of these peptides. Thus, PS mutants that 
are insensitive to sulindac sulfi de show a robust increase of Aβ38 
(Page et al., 2008). Ibuprofen, sulindac sulfi de and indomethacin, 
selectively decrease Aβ42 peptides independently of COX inhibi-
tion, whereas R-fl urbiprofen, which lacks COX inhibitory activity, 
decreases Aβ42 levels in cell culture and APP transgenic models 
(Weggen et al., 2001). In addition, cell-based screenings identifi ed 
a number of COX-2 selective NSAIDs that selectively raised Aβ42, 
and some of these also decreased Aβ38 (Kukar et al., 2005). These 
Aβ42-raising NSAIDs seem to act independently of RhoA activity 
by modulating directly γ-secretase activity.
The mechanism of action of this subgroup of NSAIDs on 
γ-secretase activity is independent of COX inhibition and most 
likely involves allosteric modulation of the γ-secretase complex 
and/or binding to APP. The fact that these compounds are effective 
in lowering or raising Aβ42 in vitro in cell-free assays supports the 
notion that they act directly on γ-secretase (Eriksen et al., 2003; 
Kukar et al., 2005). In support of this view, Aβ42-lowering NSAIDs 
change the conformation of presenilin-1 and alter the interaction of 
APP and presenilin/γ-secretase (Lleo et al., 2004). This may explain 
why some Aβ42-lowering NSAIDs reduce Aβ42 generation with-
out affecting the ε-cleavage of APP, Notch and ErbB4. Indeed, the 
selectivity of NSAID for targeting the γ-secretase cleavage of APP 
instead of other substrates may be explained by the specifi c binding 
of these compounds to APP (Kukar et al., 2008). Several familial 
AD-linked PS mutations attenuate the inhibitory effect of NSAIDs 
on Aβ42 production. The insensitivity of PS mutants to Aβ42-
 lowering NSAIDs is mimicked by non-related structural γ-secretase 
inhibitors suggesting that the binding site of these compounds are 
located in close proximity within the γ-secretase complex (Czirr 
et al., 2007).
Several studies have shown that long-term treatment with spe-
cifi c NSAIDs reduces Aβ pathology and infl ammatory responses in 
APP transgenic mice. Ibuprofen markedly reduced soluble Aβ42, 
amyloid plaques and microglia activation in APP Tg2576 mice by 
a mechanism independent of PPARγ (Yan et al., 2003). By contrast, 
acute treatment of old APPV717I transgenic mice with ibuprofen 
or the PPARγ agonist pioglitazone reduced glial infl ammation and 
amyloid plaques by decreasing BACE1 expression (Heneka et al., 
2005). Other studies using NSAIDs revealed similar reductions in 
insoluble Aβ and infl ammation, or unchanged Aβ40/42 ratio but 
decreased Aβ plaques in APP transgenic mice (Lim et al., 2000; 
Kukar et al., 2007; McGeer and McGeer, 2007). A recent study, 
however, revealed no advantage of Aβ42-lowering NSAIDS for 
preventing from AD compared to classical NSAIDs (Szekely et al., 
2008). Interestingly, therapeutic benefi ts have been reported with 
trifl usal, an anti-infl ammatory drug that inhibits COX-1 and delays 
the conversion of amnestic mild cognitive impairment to AD 
dementia. Trifl usal reduced proinfl ammatory cytokine levels (IL-
1β and TNFα), dense-core plaques and neuritic dystrophy in APP 
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Alzheimer’s disease. Neurobiol. Dis. 
(in press). [Epub ahead of print].
Czirr, E., Leuchtenberger, S., Dorner-
Ciossek, C., Schneider, A., Jucker, M., 
Koo, E. H., Pietrzik, C. U., Baumann, 
K., and Weggen, S. (2007). Insensitivity 
to Aβ42-lowering nonsteroidal anti-
infl ammatory drugs and γ-secretase 
inhibitors is common among aggres-
sive presenilin-1 mutations. J. Biol. 
Chem. 282, 24504–24513.
Dermaut, B., Kumar-Singh, S., Engelborghs, 
S., Theuns, J., Rademakers, R., Saerens, 
J., Pickut, B. A., Peeters, K., Van Den 
Broeck, M., Vennekens, K., Claes, S., 
Cruts, M., Cras, P., Martin, J. J., Van 
Broeckhoven, C., and De Deyn, P. P. 
(2004). A novel presenilin 1 mutation 
associated with Pick’s disease but not 
β-amyloid plaques. Ann. Neurol. 55, 
617–626.
De Strooper, B. (2003). Aph-1, pen-2, and 
nicastrin with presenilin generate an 
active γ-secretase complex. Neuron 
38, 9–12.
De Strooper, B. (2007). Loss-of-function 
presenilin mutations in Alzheimer 
suggested as therapeutic approach in cancer disorders caused by 
aberrant Notch signaling such as T-cell acute lymphoblastic leuke-
mia, breast cancer and ovarian carcinomas (Shih and Wang, 2007). 
However, pharmacological inhibition of PS/γ-secretase during AD 
therapeutics may have detrimental effects not only for systemic 
immune function but also for epidermal and skin barrier home-
ostasis (Rocher-Ros et al., 2010). Before clinical treatments, future 
studies should focus primarily on dissecting target specifi city of 
γ-secretase modulators. Nonetheless, inactivation of PS function 
in the forebrain results in synaptic and cognitive dysfunction fol-
lowed by neurodegeneration (Saura et al., 2004). PS inactivation 
in brain also causes infl ammatory responses in brain and periph-
ery organs. In addition, compelling evidence indicate that PS/
γ-secretase regulates maturation of T cells by regulating the Notch 
signaling pathway, whereas its inactivation causes side effects on 
immune function. Taking into consideration that PS/γ-secretase 
plays an essential function on multiple signaling pathways, a better 
understanding of the molecular mechanisms regulated by PS in 
infl ammation may lead to the development of novel therapeutic 
strategies for disorders of the nervous and immune systems.
USE OF EXPERIMENTAL ANIMALS
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Tg2576 transgenic mice (Coma et al., 2010). In old APP Tg2576 
mice,  trifl usal effi ciently rescued spatial and associative memory 
defi cits and expression of genes activated by CREB, a signaling path-
way underlying the molecular basis of synaptic plasticity (Coma 
et al., 2010). Despite the mechanism of action and the controversy 
in human trials, NSAIDs effectively reduces amyloid pathology 
and infl ammation in AD transgenic mice. It is conceivable that 
the protective effect of NSAIDs on AD pathology may be mediated 
by multiple mechanisms including among others COX, PPARγ, 
γ-secretase or a combination of these pathways.
CONCLUDING REMARKS
A large number of studies over the past years have revealed that 
PS regulate multiple signaling pathways in neurons and glia. For 
instance, the γ-secretase-dependent cleavage of APP generates the 
Aβ peptide, which plays a central role on AD pathogenesis by 
disrupting synaptic and metabolic processes essential for neuron 
survival. Several pathological hallmarks, including infl ammation, 
are exacerbated by presenilin mutations that cause early-onset 
familial AD or FTD. These studies strongly suggest γ-secretase 
as potential therapeutic target to reduce Aβ-induced pathology 
and clinical symptoms in AD. This therapeutic approach was 
successful in mice, in which partial inactivation of PS effi ciently 
reduced age- dependent Aβ accumulation and temporally rescued 
memory defi cits in an AD mouse model (Dewachter et al., 2002; 
Saura et al., 2005). However, clinical treatment with the γ-secretase 
inhibitor LY450139 in AD patients, although was well tolerated 
and reduced plasma Aβ40 levels, did not result in signifi cant dif-
ferences in cognitive or functional measures. Similarly, NSAIDs 
that reduce Aβ-associated pathology and infl ammation in AD 
transgenic mice revealed no advantage for preventing from AD 
compared to classical NSAIDs (Szekely et al., 2008). Notably, tar-
geting the Notch pathway by using γ-secretase inhibitors has been 
REFERENCES
Agdeppa, E. D., Kepe, V., Petri, A., 
Satyamurthy, N., Liu, J., Huang, S. C., 
Small, G. W., Cole, G. M., and Barrio, 
J. R. (2003). In vitro detection of (S)-
naproxen and ibuprofen binding to 
plaques in the Alzheimer’s brain 
using the positron emission tom-
ography molecular imaging probe 
2-(1-[6-[(2-[(18)F]fl uoroethyl)(me
thyl)amino]-2-naphthyl]ethylidene) 
malono nitrile. Neuroscience 117, 
723–730.
Allan, S. M., and Rothwell, N. J. (2003). 
Infl ammation in central nervous sys-
tem injury. Philos. Trans. R. Soc. Lond., 
B, Biol. Sci. 358, 1669–1677.
Arumugam, T. V., Chan, S. L., Jo, D. G., 
Yilmaz, G., Tang, S. C., Cheng, A., 
Gleichmann, M., Okun, E., Dixit, V. D., 
Chigurupati, S., Mughal, M. R., Ouyang, 
X., Miele, L., Magnus, T., Poosala, S., 
Granger, D. N., and Mattson, M. P. 
(2006). Gamma secretase-mediated 
Notch signaling worsens brain dam-
age and functional outcome in ischemic 
stroke. Nat. Med. 12, 621–623.
Bamberger, M. E., Harris, M. E., 
McDonald, D. R., Husemann, J., and 
Landreth, G. E. (2003). A cell surface 
receptor complex for fi brillar β-amy-
loid mediates microglial activation. J. 
Neurosci. 23, 2665–2674.
Bates, K. A., Fonte, J., Robertson, T. 
A., Martins, R. N., and Harvey, A. 
R. (2002). Chronic gliosis triggers 
Alzheimer’s disease-like process-
ing of amyloid precursor protein. 
Neuroscience 113, 785–796.
Beglopoulos, V., Sun, X., Saura, C. A., 
Lemere, C. A., Kim, R. D., and Shen, J. 
(2004). Reduced β-amyloid production 
and increased infl ammatory responses 
in presenilin conditional knock-out 
mice. J. Biol. Chem. 279, 46907–46914.
Bernardi, L., Tomaino, C., Anfossi, M., 
Gallo, M., Geracitano, S., Costanzo, A., 
Colao, R., Puccio, G., Frangipane, F., 
Curcio, S. A., Mirabelli, M., Smirne, N., 
Iapaolo, D., Maletta, R. G., and Bruni, 
A. C. (2009). Novel PSEN1 and PGRN 
mutations in early-onset familial fron-
totemporal dementia. Neurobiol. Aging 
30, 1825–1833.
Cervantes, S., Saura, C. A., Pomares, E., 
Gonzalez-Duarte, R., and Marfany, G. 
(2004). Functional implications of the 
presenilin dimerization: reconstitution 
of γ-secretase activity by assembly of a 
catalytic site at the dimer interface of 
two catalytically inactive presenilins. J. 
Biol. Chem. 279, 36519–36529.
Choi, S. H., Veeraraghavalu, K., Lazarov, O., 
Marler, S., Ransohoff, R. M., Ramirez, 
J. M., and Sisodia, S. S. (2008). Non-
cell-autonomous effects of presenilin 
1 variants on enrichment-mediated 
hippocampal progenitor cell prolif-
eration and differentiation. Neuron 
59, 568–580.
Coma, M., Sereno, L., Da Rocha-Souto, 
B., Scotton, T. C., España, J., Sánchez, 
M. B., Rodríguez, M., Agulló, J., 
Guardia-Laguarta, C., Garcia-Alloza, 
M., Borreli, L. A., Clarimón, J., Lleó, 
A., Bacskai, B. J., Saura, C. A., Hyman, 
B., and Gómez-Isla, T. (2010). Trifl usal 
reduces dense-core plaque load, asso-
ciated axonal alterations and infl am-
matory changes, and rescues cognition 
in a transgenic mouse model of 
Frontiers in Aging Neuroscience www.frontiersin.org May 2010 | Volume 2 | Article 16 | 9
Saura Role of presenilins on neuroinfl ammation
disease. Talking Point on the role of 
presenilin mutations in Alzheimer 
disease. EMBO Rep. 8, 141–146.
De Strooper, B., Annaert, W., Cupers, P., 
Saftig, P., Craessaerts, K., Mumm, J. S., 
Schroeter, E. H., Schrijvers, V., Wolfe, 
M. S., Ray, W. J., Goate, A., and Kopan, 
R. (1999). A presenilin-1-dependent 
γ-secretase-like protease mediates 
release of Notch intracellular domain. 
Nature 398, 518–522.
De Strooper, B., Saftig, P., Craessaerts, 
K., Vanderstichele, H., Guhde, G., 
Annaert, W., Figura, K., and Leuven, 
F. (1998). Defi ciency of presenilin-1 
inhibits the normal cleavage of amy-
loid precursor protein. Nature 391, 
387–390.
Dewachter, I., Reverse, D., Caluwaerts, N., 
Ris, L., Kuiperi, C., Van den Haute, C., 
Spittaels, K., Umans, L., Serneels, L., 
Thiry, E., Moechars, D., Mercken, M., 
Godaux, E., and Van Leuven, F. (2002). 
Neuronal defi ciency of presenilin 1 
inhibits amyloid plaque formation 
and corrects hippocampal long-term 
potentiation but not a cognitive 
defect of amyloid precursor protein 
[V717I] transgenic mice. J. Neurosci. 
22, 3445–3453.
Dewachter, I., Ris, L., Croes, S., Borghgraef, 
P., Devijver, H., Voets, T., Nilius, B., 
Godaux, E., and Van Leuven, F. (2008). 
Modulation of synaptic plasticity and 
Tau phosphorylation by wild-type and 
mutant presenilin1. Neurobiol. Aging 
29, 639–652.
Dong, S., Li, C., Wu, P., Tsien, J. Z., and 
Hu, Y. (2007). Environment enrich-
ment rescues the neurodegenerative 
phenotypes in presenilins-defi cient 
mice. Eur. J. Neurosci. 26, 101–112.
Dumanchin, C., Tournier, I., Martin, C., 
Didic, M., Belliard, S., Carlander, B., 
Rouhart, F., Duyckaerts, C., Pellissier, 
J. F., Latouche, J. B., Hannequin, D., 
Frebourg, T., Tosi, M., and Campion, 
D. (2006). Biological effects of four 
PSEN1 gene mutations causing 
Alzheimer disease with spastic para-
paresis and cotton wool plaques. Hum. 
Mutat. 27, 1063.
Eckert, A., Schindowski, K., Leutner, S., 
Luckhaus, C., Touchet, N., Czech, C., 
and Muller, W. E. (2001). Alzheimer’s 
disease-like alterations in peripheral 
cells from presenilin-1 transgenic 
mice. Neurobiol. Dis. 8, 331–342.
Eikelenboom, P., and Veerhuis, R. (1996). 
The role of complement and activated 
microglia in the pathogenesis of 
Alzheimer’s disease. Neurobiol. Aging 
17, 673–680.
Eriksen, J. L., Sagi, S. A., Smith, T. E., 
Weggen, S., Das, P., McLendon, D. 
C., Ozols, V. V., Jessing, K. W., Zavitz, 
K. H., Koo, E. H., and Golde, T. E. 
(2003). NSAIDs and enantiomers of 
flurbiprofen target γ-secretase and 
lower Aβ42 in vivo. J. Clin. Invest. 
112, 440–449.
Gaiano, N., and Fishell, G. (2002). The role 
of notch in promoting glial and neural 
stem cell fates. Annu. Rev. Neurosci. 25, 
471–490.
Gaiano, N., Nye, J., and Fishell, G. (2000). 
Radial glial identity is promoted by 
Notch1 signaling in the murine fore-
brain. Neuron 26, 395–404.
Gomez-Isla, T., Growdon, W. B., 
McNamara, M. J., Nochlin, D., Bird, 
T. D., Arango, J. C., Lopera, F., Kosik, 
K. S., Lantos, P. L., Cairns, N. J., and 
Hyman, B. T. (1999). The impact of 
different presenilin 1 and presenilin 
2 mutations on amyloid deposition, 
neurofi brillary changes and neuronal 
loss in the familial Alzheimer’s disease 
brain: evidence for other phenotype-
modifying factors. Brain 122(Pt 9), 
1709–1719.
Gomez-Tortosa, E., Barquero, S., Baron, 
M., Gil-Neciga, E., Castellanos, F., 
Zurdo, M., Manzano, S., Munoz, D. G., 
Jimenez-Huete, A., Rabano, A., Sainz, 
M. J., Guerrero, R., Gobernado, I., 
Perez-Perez, J., and Jimenez-Escrig, A. 
(2010). Clinical-genetic correlations in 
familial Alzheimer’s disease caused by 
presenilin 1 mutations. J. Alzheimers 
Dis. 19, 873–884.
Green, R. C., Schneider, L. S., Amato, D. 
A., Beelen, A. P., Wilcock, G., Swabb, E. 
A., and Zavitz, K. H. (2009). Effect of 
tarenfl urbil on cognitive decline and 
activities of daily living in patients 
with mild Alzheimer disease: a ran-
domized controlled trial. JAMA 302, 
2557–2564.
Gregory, G. C., Macdonald, V., Schofi eld, P. 
R., Kril, J. J., and Halliday, G. M. (2006). 
Differences in regional brain atrophy 
in genetic forms of Alzheimer’s dis-
ease. Neurobiol. Aging 27, 387–393.
Handler, M., Yang, X., and Shen, J. (2000). 
Presenilin-1 regulates neuronal dif-
ferentiation during neurogenesis. 
Development 127, 2593–2606.
Hardy, J., and Selkoe, D. (2002). The 
amyloid hypothesis of Alzheimer’s 
disease: progress and problems on 
the road to therapeutics. Science 297, 
353–356.
Heneka, M. T., Sastre, M., Dumitrescu-
Ozimek, L., Hanke, A., Dewachter, I., 
Kuiperi, C., O’Banion, K., Klockgether, 
T., Van Leuven, F., and Landreth, G. 
E. (2005). Acute treatment with the 
PPARγ agonist pioglitazone and ibu-
profen reduces glial infl ammation and 
Aβ1-42 levels in APPV717I transgenic 
mice. Brain 128, 1442–1453.
Hirohata, M., Ono, K., Naiki, H., and 
Yamada, M. (2005). Non-steroi-
dal anti-inflammatory drugs have 
anti-amyloidogenic effects for 
Alzheimer’s β-amyloid fi brils in vitro. 
Neuropharmacology 49, 1088–1099.
Holmes, C., Cunningham, C., Zotova, 
E., Woolford, J., Dean, C., Kerr, S., 
Culliford, D., and Perry, V. H. (2009). 
Systemic infl ammation and disease 
progression in Alzheimer disease. 
Neurology 73, 768–774.
Hutton, M. (2004). Presenilin mutations 
associated with fronto-temporal 
dementia. Ann. Neurol. 55, 604–606.
Ingelsson, M., Fukumoto, H., Newell, K. 
L., Growdon, J. H., Hedley-Whyte, E. 
T., Frosch, M. P., Albert, M. S., Hyman, 
B. T., and Irizarry, M. C. (2004). Early 
Aβ accumulation and progressive syn-
aptic loss, gliosis, and tangle formation 
in AD brain. Neurology 62, 925–931.
in t’ Veld, B. A., Ruitenberg, A., Hofman, 
A., Launer, L. J., van Duijn, C. M., 
Stijnen, T., Breteler, M. M., and 
Stricker, B. H. (2001). Nonsteroidal 
antiinfl ammatory drugs and the risk 
of Alzheimer’s disease. N. Engl. J. Med. 
345, 1515–1521.
Jack, C., Knopman, D., Jagust, W., Shaw, L., 
Aisen, P., Weiner, M., Petersen, R., and 
Tojanowski, J. (2010). Hypothetical 
model of dynamic biomarkers of the 
Alzheimer’s pathological cascade. 
Lancet Neurol. 9, 119–128.
Jiang, X., Zhang, D., Shi, J., Chen, Y., 
Zhang, P., and Mei, B. (2009). Increased 
infl ammatory response both in brain 
and in periphery in presenilins con-
ditional double knock-out mice. J. 
Alzheimers Dis. 18, 515–523.
Johnston, J. M., Burnett, P., Thomas, A. 
P., and Tezapsidis, N. (2006). Calcium 
oscillations in type-1 astrocytes, the 
effect of a presenilin 1 (PS1) mutation. 
Neurosci. Lett. 395, 159–164.
Kim, K. S., Wegiel, J., Sapienza, V., Chen, 
J., Hong, H., and, Wisniewski, H. M. 
(1997). Immunoreactivity of preseni-
lin-1 in human, rat and mouse brain. 
Brain Res. 757, 159–163.
Koo, E. H., and Kopan, R. (2004). Potential 
role of presenilin-regulated signaling 
pathways in sporadic neurodegenera-
tion. Nat. Med. 10(Suppl.), S26–S33.
Kukar, T., Murphy, M. P., Eriksen, J. L., 
Sagi, S. A., Weggen, S., Smith, T. E., 
Ladd, T., Khan, M. A., Kache, R., Beard, 
J., Dodson, M., Merit, S., Ozols, V. V., 
Anastasiadis, P. Z., Das, P., Fauq, A., 
Koo, E. H., and Golde, T. E. (2005). 
Diverse compounds mimic Alzheimer 
disease-causing mutations by aug-
menting Aβ42 production. Nat. Med. 
11, 545–550.
Kukar, T., Prescott, S., Eriksen, J. L., 
Holloway, V., Murphy, M. P., Koo, E. 
H., Golde, T. E., and Nicolle, M. M. 
(2007). Chronic administration of 
R-flurbiprofen attenuates learning 
impairments in transgenic amy-
loid precursor protein mice. BMC 
Neurosci. 8, 54.
Kukar, T. L., Ladd, T. B., Bann, M. A., 
Fraering, P. C., Narlawar, R., Maharvi, 
G. M., Healy, B., Chapman, R., 
Welzel, A. T., Price, R. W., Moore, B., 
Rangachari, V., Cusack, B., Eriksen, J., 
Jansen-West, K., Verbeeck, C., Yager, D., 
Eckman, C., Ye, W., Sagi, S., Cottrell, B. 
A., Torpey, J., Rosenberry, T. L., Fauq, 
A., Wolfe, M. S., Schmidt, B., Walsh, D. 
M., Koo, E. H., and Golde, T. E. (2008). 
Substrate-targeting γ-secretase modu-
lators. Nature 453, 925–929.
Kumar-Singh, S., Theuns, J., Van Broeck, 
B., Pirici, D., Vennekens, K., Corsmit, 
E., Cruts, M., Dermaut, B., Wang, R., 
and Van Broeckhoven, C. (2006). Mean 
age-of-onset of familial Alzheimer dis-
ease caused by presenilin mutations 
correlates with both increased Aβ42 
and decreased Aβ40. Hum. Mutat. 27, 
686–695.
Lah, J. J., Heilman, C. J., Nash, N. R., Rees, 
H. D., Yi, H., Counts, S. E., and Levey, 
A. I. (1997). Light and electron micro-
scopic localization of presenilin1 in 
primate brain. J. Neurosci. 17, 1971.
Laky, K., and Fowlkes, B. J. (2007). 
Presenilins regulate alphabeta T cell 
development by modulating TCR sig-
naling. J. Exp. Med. 204, 2115–2129.
Laky, K., and Fowlkes, B. J. (2008). Notch 
signaling in CD4 and CD8 T cell 
development. Curr. Opin. Immunol. 
20, 197–202.
Lathia, J. D., Mattson, M. P., and Cheng, 
A. (2008). Notch: from neural devel-
opment to neurological disorders. J. 
Neurochem. 107, 1471–1481.
Le, T. V., Crook, R., Hardy, J., and Dickson, 
D. W. (2001). Cotton wool plaques in 
non-familial late-onset Alzheimer 
disease. J. Neuropathol. Exp. Neurol. 
60, 1051–1061.
Lee, M. K., Slunt, H. H., Martin, L. J., 
Thinakaran, G., Kim, G., Gandy, S. 
E., Seeger, M., Koo, E., Price, D. L., 
and Sisodia, S. S. (1996). Expression 
of presenilin 1 and 2 (PS1 and PS2) in 
human and murine tissues. J. Neurosci. 
16, 7513–7525.
Lemere, C. A., Munger, J. S., Shi, G.-P., 
Natkin, L., Haass, C., Chapman, H. 
A., and Selkoe, D. J. (1995). The lyso-
somal cystein protease, cathepsin S, is 
increased in Alzheimer’s disease and 
Down syndrome brain: an immuno-
cytochemical study. Am. J. Pathol. 146, 
848–860.
Levy-Lahad, E., Wasco, W., Poorkaj, 
P., Romano, D. M., Oshima, J., 
Pettingell, H., Yu, C., Jondro, P. D., 
Schmidt, S. D., Wang, K., Crowley, A. 
C., Fu, Y-H., Guenette, S. Y., Galas, D., 
Nemens, E., Wijsman, E. M., Bird, T. 
D., Schellenberg, G. D., and Tanzi, R. 
E. (1995). Candidate gene for the chro-
mosome 1 familial Alzheimer’s disease 
locus. Science 269, 973–977.
Lim, G. P., Yang, F., Chu, T., Chen, P., 
Beech, W., Teter, B., Tran, T., Ubeda, O., 
Ashe, K. H., Frautschy, S. A., and Cole, 
Frontiers in Aging Neuroscience www.frontiersin.org May 2010 | Volume 2 | Article 16 | 10
Saura Role of presenilins on neuroinfl ammation
G. M. (2000). Ibuprofen suppresses 
plaque pathology and infl ammation 
in a mouse model for Alzheimer’s dis-
ease. J. Neurosci. 20, 5709–5714.
Lippa, C. F., Saunders, A. M., Smith, T. 
W., Swearer, J. M., Drachman, D. A., 
Ghetti, B., Nee, L., Pulaski-Salo, D., 
Dickson, D., Robitaille, Y., Bergeron, 
C., Crain, B., Benson, M. D., Farlow, 
M., Hyman, B. T., George-Hyslop, S. P., 
Roses, A. D., and Pollen, D. A. (1996). 
Familial and sporadic Alzheimer’s dis-
ease: neuropathology cannot exclude 
a fi nal common pathway. Neurology 
46, 406–412.
Lleo, A., Berezovska, O., Herl, L., Raju, S., 
Deng, A., Bacskai, B. J., Frosch, M. P., 
Irizarry, M., and Hyman, B. T. (2004). 
Nonsteroidal anti- inflammatory 
drugs lower Aβ42 and change prese-
nilin 1 conformation. Nat. Med. 10, 
1065–1066.
Lynch, M. A. (2010). Age-related neuroin-
fl ammatory changes negatively impact 
on neuronal function. Front. Neurosci. 1, 
1–8. doi: 10.3389/neuro.24.006.2009.
Mann, D. M., Takeuchi, A., Sato, S., Cairns, 
N. J., Lantos, P. L., Rossor, M. N., 
Haltia, M., Kalimo, H., and Iwatsubo, 
T. (2001). Cases of Alzheimer’s disease 
due to deletion of exon 9 of the prese-
nilin-1 gene show an unusual but char-
acteristic β-amyloid pathology known 
as ‘cotton wool’ plaques. Neuropathol. 
Appl. Neurobiol. 27, 189–196.
Maraver, A., Tadokoro, C. E., Badura, M. 
L., Shen, J., Serrano, M., and Lafaille, 
J. J. (2007). Effect of presenilins in the 
apoptosis of thymocytes and home-
ostasis of CD8+ T cells. Blood 110, 
3218–3225.
Martikainen, P., Pikkarainen, M., 
Pontynen, K., Hiltunen, M., Lehtovirta, 
M., Tuisku, S., Soininen, H., and 
Alafuzoff, I. (2009). Brain pathol-
ogy in three subjects from the same 
pedigree with PSEN1 P264L muta-
tion. Neuropathol. Appl. Neurobiol. 
36, 41–54.
McGeer, P. L., and McGeer, E. G. (2007). 
NSAIDs and Alzheimer disease: 
epidemiological, animal model and 
clinical studies. Neurobiol. Aging 28, 
639–647.
Moore, A. H., Wu, M., Shaftel, S. S., 
Graham, K. A., and O’Banion, M. K. 
(2009). Sustained expression of inter-
leukin-1beta in mouse hippocampus 
impairs spatial memory. Neuroscience 
164, 1484–1495.
Morgan, G. A., Guo, Q., Chan, S. L., Gary, 
D. S., Osborne, B. A., and Mattson, 
M. P. (2007). Defects of immune 
regulation in the presenilin-1 mutant 
knockin mouse. Neuromol. Med. 9, 
35–45.
Mrak, R. E., and Griffi n, W. S. (2005). Glia 
and their cytokines in progression of 
neurodegeneration. Neurobiol. Aging 
26, 349–354.
Muller, T., Meyer, H. E., Egensperger, 
R., and Marcus, K. (2008). The amy-
loid precursor protein intracellular 
domain (AICD) as modulator of gene 
expression, apoptosis, and cytoskeletal 
dynamics-relevance for Alzheimer’s 
disease. Prog. Neurobiol. 85, 393–406.
Munch, G., Gasic-Milenkovic, J., Dukic-
Stefanovic, S., Kuhla, B., Heinrich, K., 
Riederer, P., Huttunen, H. J., Founds, 
H., and Sajithlal, G. (2003). Microglial 
activation induces cell death, inhibits 
neurite outgrowth and causes neurite 
retraction of differentiated neuroblas-
toma cells. Exp. Brain. Res. 150, 1–8.
Nadler, Y., Alexandrovich, A., Grigoriadis, 
N., Hartmann, T., Rao, K. S., Shohami, 
E., and Stein, R. (2008). Increased 
expression of the γ-secretase com-
ponents presenilin-1 and nicastrin 
in activated astrocytes and microglia 
following traumatic brain injury. Glia 
56, 552–567.
Nagele, R. G., D’Andrea, M. R., Lee, H., 
Venkataraman, V., and Wang, H. Y. 
(2003). Astrocytes accumulate Aβ42 
and give rise to astrocytic amyloid 
plaques in Alzheimer disease brains. 
Brain Res. 971, 197–209.
Ni, C., Murphy, M., Golde, T., and 
Carpenter, G. (2001). γ-Secretase 
cleavage and nuclear localization 
of ErbB-4 receptor tyrosine kinase. 
Science 294, 2179–2181.
Nochlin, D., van Belle, G., Bird, T. D., and 
Sumi, S. M. (1993). Comparison of the 
severity of neuropathologic changes 
in familial and sporadic Alzheimer’s 
disease. Alzheimer Dis. Assoc. Disord. 
7, 212–222.
Ong, C. T., Sedy, J. R., Murphy, K. M., and 
Kopan, R. (2008). Notch and prese-
nilin regulate cellular expansion and 
cytokine secretion but cannot instruct 
Th1/Th2 fate acquisition. PLoS 
ONE 3, e2823. doi:10.1371/journal.
pone.0002823
Page, R. M., Baumann, K., Tomioka, M., 
Perez-Revuelta, B. I., Fukumori, A., 
Jacobsen, H., Flohr, A., Luebbers, T., 
Ozmen, L., Steiner, H., and Haass, C. 
(2008). Generation of Aβ38 and Aβ42 
is independently and differentially 
affected by familial Alzheimer disease-
associated presenilin mutations and 
γ-secretase modulation. J. Biol. Chem. 
283, 677–683.
Parachikova, A., Agadjanyan, M. G., 
Cribbs, D. H., Blurton-Jones, M., 
Perreau, V., Rogers, J., Beach, T. G., and 
Cotman, C. W. (2007). Infl ammatory 
changes parallel the early stages of 
Alzheimer disease. Neurobiol. Aging 
28, 1821–1833.
Peers, C., Dallas, M. L., Boycott, H. E., 
Scragg, J. L., Pearson, H. A., and 
Boyle, J. P. (2009). Hypoxia and 
 neurodegeneration. Ann. N. Y. Acad. 
Sci. 1177, 169–177.
Peers, C., Smith, I. F., Boyle, J. P., and 
Pearson, H. A. (2004). Remodelling 
of Ca2+ homeostasis in type I cortical 
astrocytes by hypoxia: evidence for 
association with Alzheimer’s disease. 
Biol. Chem. 385, 285–289.
Raux, G., Gantier, R., Thomas-Anterion, 
C., Boulliat, J., Verpillat, P., Hannequin, 
D., Brice, A., Frebourg, T., and 
Campion, D. (2000). Dementia with 
prominent frontotemporal features 
associated with L113P presenilin 1 
mutation. Neurology 55, 1577–1578.
Rocher-Ros, V., Marco, S., Mao, J. H., 
Gines, S., Metzger, D., Chambon, P., 
Balmain, A., and Saura, C. A. (2010). 
Presenilin modulates EGFR signaling 
and cell transformation by regulating 
the ubiquitin ligase Fbw7. Oncogene 
(in press). [Epub ahead of print]
Rogaev, E. I., Sherrington, R., Rogaeva, 
E. A., Levesque, G., Ikeda, M., Liang, 
Y., Chi, H., Lin, C., Holamn, K., 
Tsuda, T., Mar, L., Sorbi, S., Nacmias, 
B., Piacentini, S., Amaducci, L., 
Chumakov, I., Cohen, D., Lannfelt, L., 
Fraser, P. E., Rommens, J. M., and St. 
George-Hyslop, P. H. (1995). Familial 
Alzheimer’s disease in kindreds with 
missense mutations in a gene on chro-
mosome 1 related to the Alzheimer’s 
disease type 3 gene. Nature 376, 
775–778.
Sardi, S. P., Murtie, J., Koirala, S., Patten, B. 
A., and Corfas, G. (2006). Presenilin-
dependent ErbB4 nuclear signaling 
regulates the timing of astrogen-
esis in the developing brain. Cell 127, 
185–197.
Sastre, M., Dewachter, I., Rossner, S., 
Bogdanovic, N., Rosen, E., Borghgraef, 
P., Evert, B. O., Dumitrescu-Ozimek, 
L., Thal, D. R., Landreth, G., Walter, 
J., Klockgether, T., van Leuven, F., and 
Heneka, M. T. (2006). Nonsteroidal 
anti-infl ammatory drugs repress β-
secretase gene promoter activity by the 
activation of PPARgamma. Proc. Natl. 
Acad. Sci. U.S.A. 103, 443–448.
Saura, C. A., Chen, G., Malkani, S., Choi, S. 
Y., Takahashi, R. H., Zhang, D., Gouras, 
G. K., Kirkwood, A., Morris, R. G., and 
Shen, J. (2005). Conditional inactiva-
tion of presenilin-1 prevents amyloid 
accumulation and temporarily rescues 
contextual and spatial working mem-
ory impairments in amyloid precursor 
protein transgenic mice. J. Neurosci. 
25, 6755–6764.
Saura, C. A., Choi, S. Y., Beglopoulos, 
V. , Malkani , S . , Zhang, D. , 
Shankaranarayana Rao, B. S., Chattarji, 
S., Kelleher, R. J. III, Kandel, E. R., Duff, 
K., Kirkwood, A., and Shen, J. (2004). 
Loss of presenilin function causes 
impairments of memory and  synaptic 
plasticity followed by age-depend-
ent neurodegeneration. Neuron 42, 
23–36.
Saura, C. A., Tomita, T., Davenport, 
F., Harris, C. L., Iwatsubo, T., and 
Thinakaran, G. (1999). Evidence that 
intramolecular associations between 
presenilin domains are obligatory for 
endoproteolytic processing. J. Biol. 
Chem. 274, 13818–13823.
Selkoe, D. J. (2002). Alzheimer’s disease 
is a synaptic failure. Science 298, 
789–791.
Shen, J., and Kelleher R. J. III. (2007). The 
presenilin hypothesis of Alzheimer’s 
disease: evidence for a loss-of-function 
pathogenic mechanism. Proc. Natl. 
Acad. Sci. U.S.A. 104, 403–409.
Shepherd, C., McCann, H., and Halliday, 
G. M. (2009). Variations in the neu-
ropathology of familial Alzheimer’s 
disease. Acta Neuropathol. 118, 
37–52.
Shepherd, C. E., Grace, E. M., Mann, 
D. M., and Halliday, G. M. (2007). 
Relationship between neuronal loss 
and ‘infl ammatory plaques’ in early 
onset Alzheimer’s disease. Neuropathol. 
Appl. Neurobiol. 33, 328–333.
Shepherd, C. E., Gregory, G. C., Vickers, J. 
C., and Halliday, G. M. (2005). Novel 
‘inflammatory plaque’ pathology 
in presenilin-1 Alzheimer’s disease. 
Neuropathol. Appl. Neurobiol. 31, 
503–511.
Sherrington, R., Rogaev, E. I., Liang, Y., 
Rogaeva, E. A., Levesque, G., Ikeda, M., 
Chi, H., Lin, C., Li, G., Holman, K., 
Tsuda, T., Mar, L., Foncin, J-F, Bruni, 
A. C., Montesi, M. P., Sorbi, S., Rainero, 
I., Pinessi, L., Nee, L., Chumakov, I., 
Pollen, D. A., Roses, A. D., Fraser, P. 
E., Rommens, J. M., and St. George-
Hyslop, P. H. (1995). Cloning of a 
novel gene bearing missense mutations 
in early onset familial Alzheimer’s dis-
ease. Nature 375, 754–760.
Shih, I. M., and Wang, T. L. (2007). 
Notch signaling, γ-secretase inhibi-
tors, and cancer therapy. Cancer Res. 
67, 1879–1882.
Sokolova, A., Hill, M. D., Rahimi, F., 
Warden, L. A., Halliday, G. M., and 
Shepherd, C. E. (2009). Monocyte che-
moattractant protein-1 plays a domi-
nant role in the chronic infl ammation 
observed in Alzheimer’s disease. Brain 
Pathol. 19, 392–398.
Stewart, W. F., Kawas, C., Corrada, M., and 
Metter, E. J. (1997). Risk of Alzheimer’s 
disease and duration of NSAID use. 
Neurology 48, 626–632.
Sudo, S., Shiozawa, M., Cairns, N. J., and 
Wada, Y. (2005). Aberrant accentua-
tion of neurofi brillary degeneration in 
the hippocampus of Alzheimer’s dis-
ease with amyloid precursor protein 
Frontiers in Aging Neuroscience www.frontiersin.org May 2010 | Volume 2 | Article 16 | 11
Saura Role of presenilins on neuroinfl ammation
717 and presenilin-1 gene mutations. 
J. Neurol. Sci. 234, 55–65.
Szekely, C. A., Green, R. C., Breitner, J. 
C., Ostbye, T., Beiser, A. S., Corrada, 
M. M., Dodge, H. H., Ganguli, M., 
Kawas, C. H., Kuller, L. H., Psaty, 
B. M., Resnick, S. M., Wolf, P. A., 
Zonderman, A. B., Welsh-Bohmer, K. 
A., and Zandi, P. P. (2008). No advan-
tage of Aβ42-lowering NSAIDs for 
prevention of Alzheimer dementia in 
six pooled cohort studies. Neurology 
70, 2291–2298.
Takasugi, N., Tomita, T., Hayashi, I., 
Tsuruoka, M., Niimura, M., Takahashi, 
Y., Thinakaran, G., and Iwatsubo, T. 
(2003). The role of presenilin cofac-
tors in the γ-secretase complex. Nature 
422, 438–441.
Tenner, A. J. (2001). Complement in 
Alzheimer’s disease: opportunities for 
modulating protective and pathogenic 
events. Neurobiol. Aging 22, 849–861.
Thinakaran, G., Borchelt, D. R., Lee, 
M. K., Slunt, H. H., Spitzer, L., Kim, 
G., Rotovitsky, T., Davenport, F., 
Nordstedt, C., Seeger, M., Hardy, J., 
Levey, A. I., Gandy, S. E., Jenkins, N. 
A., Copeland, N. G., Price, D. L., and 
Sisodia, S. S. (1996). Endoproteolysis 
of presenilin 1 and accumulation of 
processed derivatives in vivo. Neuron 
17, 181–190.
Tournoy, J., Bossuyt, X., Snellinx, A., 
Regent, M., Garmyn, M., Serneels, L., 
Saftig, P., Craessaerts, K., De Strooper, 
B., and Hartmann, D. (2004). Partial 
loss of presenilins causes seborrheic 
keratosis and autoimmune dis-
ease in mice. Hum. Mol. Genet. 13, 
1321–1331.
Vlad, S. C., Miller, D. R., Kowall, N. W., 
and Felson, D. T. (2008). Protective 
effects of NSAIDs on the develop-
ment of Alzheimer disease. Neurology 
70, 1672–1677.
Weggen, S., Diehlmann, A., Buslei, R., 
Beyreuther, K., and Bayer, T. A. (1998). 
Prominent expression of presenilin-1 
in senile plaques and reactive astro-
cytes in Alzheimer’s disease brain. 
Neuroreport 9, 3279–3283.
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. 
A., Wang, R., Pietrzik, C. U., Findlay, 
K. A., Smith, T. E., Murphy, M. P., 
Bulter, T., Kang, D. E., Marquez-
Sterling, N., Golde, T. E., and Koo, E. 
H. (2001). A subset of NSAIDs lower 
amyloidogenic Aβ42 independently 
of cyclooxygenase activity. Nature 414, 
212–216.
Weggen, S., Rogers, M., and Eriksen, J. 
(2007). NSAIDs: small molecules for 
prevention of Alzheimer’s disease or 
precursors for future drug develop-
ment? Trends Pharmacol. Sci. 28, 
536–543.
Weyand, N. J., Calton, C. M., Higashi, D. 
L., Kanack, K. J., and So, M. (2010). 
Presenilin/γ-secretase cleaves CD46 
in response to Neisseria infection. J. 
Immunol. 184, 694–701.
Woodhouse, A., Shepherd, C. E., Sokolova, 
A., Carroll, V. L., King, A. E., Halliday, 
G. M., Dickson, T. C., and Vickers, 
J. C. (2009). Cytoskeletal alterations 
differentiate presenilin-1 and sporadic 
Alzheimer’s disease. Acta Neuropathol. 
117, 19–29.
Wyss-Coray, T., Lin, C., Yan, F., Yu, G.-Q., 
Rohde, M., McConlogue, L., Masliah, 
E., and Mucke, L. (2001). TGF-β1 pro-
motes microglial amyloid-β clearance 
and reduces plaque burden in trans-
genic mice. Nat. Med. 7, 612–618.
Wyss-Coray, T., Loike, J. D., Brionne, T. C., 
Lu, E., Anankov, R., Yan, F., Silverstein, 
S. C., and Husemann, J. (2003). Adult 
mouse astrocytes degrade amyloid-
β in vitro and in situ. Nat. Med. 9, 
453–457.
Yagi, T., Giallourakis, C., Mohanty, S., 
Scheidig, C., Shen, J., Zheng, H., Xavier, 
R. J., and Shaw, A. C. (2008). Defective 
signal transduction in B lymphocytes 
lacking presenilin proteins. Proc. Natl. 
Acad. Sci. U.S.A. 105, 979–984.
Yan, Q., Zhang, J., Liu, H., Babu-Khan, 
S., Vassar, R., Biere, A. L., Citron, M., 
and Landreth, G. (2003). Anti-infl am-
matory drug therapy alters β-amyloid 
processing and deposition in an ani-
mal model of Alzheimer’s disease. J. 
Neurosci. 23, 7504–7509.
Zekanowski, C., Golan, M. P., Krzysko, 
K. A., Lipczynska-Lojkowska, W., 
Filipek, S., Kowalska, A., Rossa, 
G., Peplonska, B., Styczynska, M., 
Maruszak, A., Religa, D., Wender, 
M., Kulczycki, J., Barcikowska, M., 
and Kuznicki, J. (2006). Two novel 
presenilin 1 gene mutations con-
nected with frontotemporal demen-
tia-like clinical phenotype: genetic 
and bioinformatic assessment. Exp. 
Neurol. 200, 82–88.
Zhang, Z., Nadeau, P., Song, W., Donoviel, 
D., Yuan, M., Bernstein, A., and 
Yankner, B. (2000). Presenilins are 
required for γ-secretase cleavage of 
β-APP and transmembrane cleavage 
of Notch-1. Nat. Cell Biol. 2, 463.
Conflict of Interest Statement: The 
author declares that the research was 
conducted in the absence of any com-
mercial or financial relationships that 
could be construed as a potential confl ict 
of interest.
Received: 18 March 2010; paper pend-
ing published: 29 March 2010; accepted: 
08 April 2010; published online: 18 May 
2010.
Citation: Saura CA (2010) Presenilin/γ-sec
retase and infl ammation. Front. Ag. Neuro
sci. 2:16. doi: 10.3389/fnagi.2010.00016
Copyright © 2010 Saura. This is an open-
access article subject to an exclusive license 
agreement between the authors and the 
Frontiers Research Foundation, which 
permits unrestricted use, distribution, and 
reproduction in any medium, provided the 
original authors and source are credited.
